Search

Displaying results 4281 - 4290 of 9705 in total
  1. Drug

    Strontium malonate

    go.drugbank.com/drugs/DB05732
    Investigational

    Strontium malonate is being developed as a novel orally available pharmaceutical for the treatment and prevention of osteoporosis. It is being developed by Osteologix Inc.

  2. Drug

    MIV-701

    go.drugbank.com/drugs/DB05736
    Experimental

    MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.

  3. Drug

    Varespladib methyl

    go.drugbank.com/drugs/DB05737
    Investigational

    Varespladib methyl has been investigated for the treatment of Acute Coronary Syndrome. Studies showed that Varespladib methyl treatment resulted in significant positive changes on lipoproteins and inflammation.

  4. Drug

    CRx-139

    go.drugbank.com/drugs/DB05744
    Experimental

    It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects.

  5. Drug

    RP01

    go.drugbank.com/drugs/DB05751
    Experimental

    RP01 is a novel anti-IgE immunotherapy for allergic individuals.

  6. Drug

    ATX-201

    go.drugbank.com/drugs/DB05765
    Investigational

    ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis.

  7. Drug

    Andrographolide

    go.drugbank.com/drugs/DB05767
    Investigational

    Andrographolide (HMPL-004) is a botanical product extracted from a herb that occurs naturally in China.

  8. Drug

    Trastuzumab emtansine

    go.drugbank.com/drugs/DB05773
    ApprovedInvestigational

    Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity. … Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  9. Drug

    CRx-401

    go.drugbank.com/drugs/DB05775
    Experimental

    It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic dose of bezafibrate, an anti-cholesterol agent. … CRx-401 is a novel insulin sensitizer designed to provide anti-diabetic activity without promoting weight gain.

  10. Drug

    IC41

    go.drugbank.com/drugs/DB05776
    Investigational

    The vaccine consists of five synthetic peptides (IPEP83, 84, 87, 89,1426) harboring HCV CD4 and CD8 T-cell epitopes and the synthetic adjuvant poly-L-arginine. … IC41 is a therapeutic peptide vaccine. It is being devloped by Intercell AG for the treatment of hepatitis C.